Ratg denied for failing step therapy by Humana?

Humana Medicare Advantage plans must follow CMS coverage guidelines, and services must be provided according to Medicare coverage guidelines established by the Centers for Medicare & Medicaid Services (CMS), under which all medical care, services, supplies and equipment must be medically necessary . Under CMS NCD 260.7, the FDA has approved lymphocyte immune globulin, anti-thymocyte globulin (equine) for the management of allograft rejection episodes in renal transplantation, it is covered under Medicare when used for this purpose, and other forms of lymphocyte globulin preparation that the FDA approves for this indication may be covered . The FDA-labeled indication for rabbit ATG is that Thymoglobulin (anti-thymocyte globulin, rabbit) is indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression , with the approved regimen being 1.5 mg/kg of body weight administered daily for 4 to 7 days . Per FDA labeling, Thymoglobulin is contraindicated in patients with a history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or who have active acute or chronic infections that contraindicate any additional immunosuppression , and dose reductions are required when the WBC count is between 2,000 and 3,000 cells/mm3 or if the platelet count is between 50,000 and 75,000 cells/mm3 . Humana requires prior authorization through its transplant network: preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300 or by phone at 866-421-5663 , and Humana MA may apply step therapy requirements for some drugs under its Part B Step Therapy Preferred Drug List. To prevent disruption of care, Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment, though Humana may review services furnished during an active course of treatment against permissible coverage criteria when determining payment .

- For kidney transplant rejection prophylaxis or treatment, the request aligns squarely with the FDA label: Thymoglobulin is indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression , and the drug is indicated for management of allograft rejection episodes in renal transplantation and is covered under Medicare when used for this purpose per CMS NCD 260.7 - KDIGO clinical practice guidelines support ATG-based induction in kidney transplant recipients, particularly those at high immunologic risk; anti-thymocyte globulin is a highly efficient induction agent that can prevent acute rejection and delayed graft function and is widely used for biopsy-confirmed acute rejection reversal and steroid-resistant rejection - For steroid-resistant or vascular rejection, ATG is the guideline-endorsed standard: ATG is a pivotal immunosuppressive therapy utilized in the management of T-cell-mediated rejection and steroid-resistant rejection among renal transplant recipients ; an IL-2 receptor antagonist (basiliximab) is not an appropriate substitute for treatment of established rejection, so step-therapy requirements should be waived - Dosing requested matches the FDA-approved regimen of 1.5 mg/kg of body weight administered daily for 4 to 7 days for induction, or a 7 to 14 day course of daily infusion of 1.5 mg/kg of Thymoglobulin for treatment of acute rejection, consistent with the package insert and LiverTox/NIH summaries - Thymoglobulin is preferred over equine ATG in high-risk recipients: multiple studies have indicated that thymoglobulin is favored in comparison to other induction agents for patients who have increased risk of developing post-transplant complications, such as elderly patients, patients undergoing a repeat transplantation, and patients in which minimization of use of steroids or CNIs post-operation is recommended — relevant for the Medicare Advantage population - Humana's own policy framework grants continuity-of-care protection: Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment , and members can request expedited exception reviews for step therapy prior authorization requests - Contraindication-based denials should be rebutted with documentation that the patient has no history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or active acute or chronic infections that contraindicate any additional immunosuppression , satisfying the only FDA-labeled contraindications

## Why Humana Requires Step Therapy for rATG — and Why You Can Appeal

Rabbit anti-thymocyte globulin (rATG) is a powerful immunosuppressive biological agent used primarily in solid-organ transplantation (induction and rejection treatment) and in serious hematologic conditions including aplastic anemia. Humana's step-therapy requirement means its policy expects that certain other immunosuppressive agents be tried and documented as inadequate before rATG will be authorized. In many clinical situations — acute rejection, severe aplastic anemia, or specific transplant protocols — this sequencing is clinically inappropriate or dangerous, making the step-therapy denial directly appealable.

## Why This Denial Is Appealable

Step-therapy protocols are written for broad populations and cannot anticipate every individual patient's presentation. Federal and many state step-therapy reform laws (your rights depend on your plan type and state) require insurers to grant exceptions when step therapy is contraindicated, has already failed, or would result in clinically significant harm or disease progression. If your transplant or hematology specialist has determined that rATG is the appropriate first-line or urgently required agent for your situation, that clinical judgment — supported by the applicable professional society guidelines — forms the basis of a step-therapy exception request.

## Federal Appeal Framework

• Internal appeal / step-therapy exception: File both simultaneously if your plan allows; document the clinical rationale for bypassing the required prior step.
• ACA Section 2719 external review: Available after exhausting internal remedies for non-grandfathered plans. The external-review window is approximately 4 months from the final internal denial date.
• Expedited review: Request expedited processing if delaying rATG would seriously jeopardize your health — this is frequently applicable in acute rejection or severe aplastic anemia settings.
• ERISA Section 503: Employer-sponsored plans must provide full-and-fair review, including access to the specific clinical criteria driving the step-therapy requirement.

## Appeal Timeline

1. Obtain the denial letter and the step-therapy policy language in writing. 2. Confirm your plan type (ERISA / ACA marketplace / state-regulated) to understand which step-therapy exception rights apply. 3. Submit the internal appeal with supporting documentation. 4. If denied, file for independent external review immediately.

## Documentation to Gather

• Diagnosis and clinical urgency: Records documenting the underlying condition and acuity (e.g., biopsy-confirmed rejection, hematology workup).
• Prior therapy history: Any immunosuppressive agents already tried, with dates, doses used, and specific reasons they were inadequate or could not be used (documented in the chart).
• Prescriber medical-necessity letter: Your specialist should state why rATG is medically necessary at this stage and why the step-therapy sequence is clinically inappropriate for your case, citing applicable professional society guidelines (e.g., the relevant transplant or hematology society guidance).
• Clinical severity documentation: Recent clinical notes, labs, or imaging demonstrating disease status.

## Criteria-Mapping Structure

Obtain Humana's step-therapy policy for rATG. For each required prior step, document whether it was tried or why it could not be tried:

| Step-Therapy Requirement | Chart Documentation | |---|---| | Required prior agent #1 tried or contraindicated | Treatment record or prescriber attestation with clinical rationale | | Required prior agent #2 tried or contraindicated | Treatment record or prescriber attestation with clinical rationale | | Adequate trial duration OR exception basis | Dates and documented outcome; or specialist letter citing clinical exception |

Match each criterion precisely to your records. A well-structured letter from your specialist mapping chart facts to each policy requirement is the most effective tool in this appeal.